A breakthrough weight loss medication is now available through the NHS, but accessing it isn't as straightforward as visiting your GP. New government guidance reveals exactly how eligible patients can obtain Wegovy, a drug that's showing remarkable results for people struggling with obesity-related health conditions.
Wegovy, known medically as semaglutide, works by mimicking a natural hormone that helps regulate appetite in the brain. The National Institute for Health and Care Excellence (NICE) has approved it for adults with a Body Mass Index (BMI) of 35 or above who also have weight-related health problems such as type 2 diabetes or high blood pressure. For people from certain ethnic minority groups—who face higher health risks at lower weights—the threshold drops to a BMI of 30-34.9 with a related health condition.
Here's what patients need to know: you cannot simply ask your GP for Wegovy. The Department of Health and Social Care guidance makes clear that NHS provision is strictly through specialist weight management services. Your GP must refer you to these specialist teams, where healthcare professionals will assess whether you're suitable for the medication as part of a comprehensive programme that includes dietary support, exercise guidance, and behavioural therapy.
Wegovy is also available privately, but the DHSC urges caution. Patients considering this route should ensure they're consulting registered healthcare professionals who can provide proper medical oversight and discuss potential side effects. Private prescriptions come with substantial costs that the NHS won't reimburse, and because the medication is designed for long-term use, these expenses will be ongoing.
The rollout comes as obesity rates continue climbing across the UK, offering new hope for those who've struggled with conventional weight loss methods. However, high global demand and supply chain challenges mean availability remains limited, leading to a phased introduction whilst the DHSC monitors supply levels to ensure fair access.
The Labour Party's Shadow Health Secretary welcomed the new treatment but warned that the government must ensure specialist NHS services have sufficient capacity to meet demand. They called for a clear plan to expand these services, preventing long waiting lists for eligible patients and emphasising that medication must complement, not replace, broader public health initiatives.